Emerald Mutual Fund Advisers Trust’s Ocular Therapeutix OCUL Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-680,588	Closed	-$1.91M	–	255
2022 Q4	$1.91M	Sell	680,588 -401,515	-37%	-$1.33M	0.12%	126
2022 Q3	$4.49M	Buy	1,082,103 +37,371	+4%	+$188K	0.28%	104
2022 Q2	$4.2M	Sell	1,044,732 -48,416	-4%	-$183K	0.24%	112
2022 Q1	$5.41M	Buy	1,093,148 +95,922	+10%	+$532K	0.24%	117
2021 Q4	$6.95M	Buy	997,226 +621,420	+165%	+$4.83M	0.25%	113
2021 Q3	$3.76M	Sell	375,806 -942,931	-72%	-$10.6M	0.13%	136
2021 Q2	$18.7M	Sell	1,318,737 -35,159	-3%	-$534K	0.61%	67
2021 Q1	$22.2M	Buy	1,353,896 +232,268	+21%	+$4.47M	0.74%	54
2020 Q4	$23.2M	Buy	+1,121,628	New	+$16.7M	0.81%	46

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's OCUL Position: Q1 2023 in Review

Emerald Mutual Fund Advisers Trust sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 680,588 shares — an estimated $1.91M sold.

Emerald Mutual Fund Advisers Trust first reported a position in OCUL in Q4 2020 and held it in 9 quarters. The position peaked at $23.2M in Q4 2020. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

Emerald Mutual Fund Advisers Trust reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 680,588 Ocular Therapeutix shares in Q1 2023, an estimated $1.91M.
Emerald Mutual Fund Advisers Trust first reported a position in Ocular Therapeutix in Q4 2020 and held it in 9 quarters.
Emerald Mutual Fund Advisers Trust's Ocular Therapeutix position peaked at $23.2M in Q4 2020.
127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2023, filed 4 May 2023.